These tumor antigens are the primary targets used in ACT for HCC and mainly fall into one of the three categories, including tumor-associated antigens (e.g., AFP, GPC-3), viral-derived cancer antigens (VHB, VHC), and cancer–testis antigens (e.g., NY-ESO-1, MAGE). Here, GPC3 is linked to hepatocellular carcinoma.